posted on 2013-10-22, 00:00authored byCharlotte Hvaring, Snezana Vujicic, Jan O. Aasly, Douglas L. Feinstein, Linda R. White, Anne I. Boullerne
This study has established the presence of IgM against S-nitrosylated proteins in
cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients using S-nitrosocysteine epitope
(anti-SNOcys) as previously shown in serum. Anti-SNOcys IgM increased significantly in
CSF during relapsing-remitting MS compared to milder neurological conditions. Evidence
from albumin, IgG and IgM suggest that the production of anti-SNOcys IgM is intrathecal
rather than the result of ingress from serum. Two correlations during relapse: between CSF
level of anti-SNOcys IgM and time elapsed since relapse onset; and between CSF and serum
anti-SNOcys IgM levels, suggest that this antibody may have potential as a biomarker.
Funding
This work was supported by the National Multiple Sclerosis Society, USA (PP1366 to A.I.B.),
and a scholarship from the Norwegian University of Science and Technology (C.H.).
History
Publisher Statement
NOTICE: This is the author’s version of a work that was accepted for publication in Journal of Neuroimmunology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Neuroimmunology, Issue 1-2, 2013 DOI: 10.1016/j.jneuroim.2012.12.011